Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors
Crossref DOI link: https://doi.org/10.1007/s00280-016-3011-0
Published Online: 2016-03-26
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yoshiba, Satoshi
Jansen, Mendel
Matsushima, Nobuko
Chen, Shuquan
Mendell, Jeanne
Funding for this research was provided by:
Daiichi Sankyo Pharma Development
Text and Data Mining valid from 2016-03-26